A Phase 2 interventional study of silodosin and placebo in Ureteral Calculi, Kidney Stones and Urolithiasis, sponsored by Watson Pharmaceuticals. Completed at 27 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-08-11.
Sponsored by Watson Pharmaceuticals (part of AbbVie) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Ureteral Calculi with a site in United States — 2 open to participants now, 3 under way, none of them phase 3. Ureteral Calculi · United States.
Among the 13 studies in Ureteral Calculi with a site in United States, this one has the largest enrollment, is the only one that started in 2010, is the only one in phase 2, and was the 4th registered.
51 studies on the registry are indexed under Ureteral Calculi; 15 are open to participants now.
Browse Ureteral Calculi studies →2 of the 13 studies in Ureteral Calculi with a site in United States are open now. Recruiting first, the newest first:
Avvio Medical · Sites in United States
Ages 21+
University of Washington · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 11 Ureteral Calculi studies recruiting now, 5 (45%) set no upper age limit and 5 (45%) stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 239 is above the median of 100 across 43 interventional studies indexed under Ureteral Calculi.
Median enrollment 74 across the 13 interventional studies. Of the 9 that completed or were terminated, 5 (56%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 13 have an industry lead sponsor. The 10 most frequent:
This study is registered under Watson Pharmaceuticals, one of the names counted as AbbVie. Under that name alone:
Watson Pharmaceuticals is the lead sponsor of 30 studies on the registry; none are open to participants now.
AbbVie has 1 study filed under Ureteral Calculi — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 13 studies in Ureteral Calculi with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to assess if patients treated with silodosin will have a higher spontaneous passage rate of their ureteral stone than those treated with placebo.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: silodosin
Drug: placebo
one silodosin 8 mg capsule orally, once daily, with food for up to 4 weeks
one placebo capsule orally, once daily, with food for up to 4 weeks
Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.
The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes only those stones located in the distal ureter.
Time frame: 4 weeks
Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures.
The primary efficacy variable is the occurrence of spontaneous stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes all ureteral stones, regardless of location in the ureter.
Time frame: 4 weeks
Time to Spontaneous Stone Passage (Distal Stones)
Time to stone passage for distally-located stones is assessed by entries in subject diaries.
Time frame: 4 weeks
Outpatient Narcotic Analgesic Use for Pain Relief
Narcotic analgesic use was assessed through a subject diary. Analysis was performed on the number of days with analgesic use.
Time frame: 4 weeks
Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones)
At each study visit, subjects were given a Brief Pain Inventory (BPI) Questionnaire to complete. The BPI collects subject-reported pain severity scores and assesses impact of pain upon the subject's daily life, on a 10-point scale (with 10 being the greatest severity/impact). Analysis was change from baseline to week 4.
Time frame: 4 weeks
Time to Spontaneous Stone Passage (All Stones)
Time to stone passage for all ureteral stones (regardless of location) is assessed by entries in subject diaries.
Time frame: 4 weeks
| Milestone | Silodsosin | Placebo |
|---|---|---|
| Started | 119 | 120 |
| Completed | 108 | 106 |
| Not completed | 11 | 14 |
The primary efficacy variable is the occurrence of spontaneous distal stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes only those stones located in the distal ureter.
| participants | Silodsosin | Placebo |
|---|---|---|
| Spontaneous Stone Passage (Distal Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures. | 36 | 27 |
Time to stone passage for distally-located stones is assessed by entries in subject diaries.
| days | Silodsosin | Placebo |
|---|---|---|
| Time to Spontaneous Stone Passage (Distal Stones) | 19.6 ± 1.61 | 22.0 ± 1.47 |
Narcotic analgesic use was assessed through a subject diary. Analysis was performed on the number of days with analgesic use.
| Days | Silodsosin | Placebo |
|---|---|---|
| Outpatient Narcotic Analgesic Use for Pain Relief | 5.8 ± 8.0 | 5.5 ± 6.8 |
At each study visit, subjects were given a Brief Pain Inventory (BPI) Questionnaire to complete. The BPI collects subject-reported pain severity scores and assesses impact of pain upon the subject's daily life, on a 10-point scale (with 10 being the greatest severity/impact). Analysis was change from baseline to week 4.
| units on a scale | Silodsosin | Placebo |
|---|---|---|
| Change From Baseline in Average Score on the Brief Pain Inventory (Distal Stones) | -2.6 ± 2.5 | -1.9 ± 3.1 |
The primary efficacy variable is the occurrence of spontaneous stone passage within 4 weeks, as determined by radiography. For this outcome measure, analysis includes all ureteral stones, regardless of location in the ureter.
| participants | Silodsosin | Placebo |
|---|---|---|
| Spontaneous Stone Passage (All Stones) Without Need for Emergency Department Visits, Hospital Admissions, Surgical Intervention, or Other Interventional Procedures. | 60 | 52 |
Time to stone passage for all ureteral stones (regardless of location) is assessed by entries in subject diaries.
| days | Silodsosin | Placebo |
|---|---|---|
| Time to Spontaneous Stone Passage (All Stones) | 22.3 ± 1.02 | 22.9 ± 1.00 |
Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Silodsosin | — | 2/119 (1.7%) | 27/119 (22.7%) |
| Placebo | — | 2/120 (1.7%) | 8/120 (6.7%) |
| Event | Silodsosin | Placebo |
|---|---|---|
| Renal colicRenal and urinary disorders | 2/119 | 2/120 |
| Event | Silodsosin | Placebo |
|---|---|---|
| Retrograde ejaculationReproductive system and breast disorders | 11/119 | 1/120 |
| NauseaGastrointestinal disorders | 9/119 | 2/120 |
| DizzinessNervous system disorders | 8/119 | 2/120 |
| HeadacheNervous system disorders | 4/119 | 0/120 |
| VomitingGastrointestinal disorders | 4/119 | 4/120 |
| Age, Continuous(years) | Silodsosin | Placebo | Total |
|---|---|---|---|
| Mean | 47.4 ± 12.5 | 46.7 ± 15.2 | 47.0 ± 13.9 |
| Sex: Female, Male(Participants) | Silodsosin | Placebo | Total |
|---|---|---|---|
| Female | 47 | 36 | 83 |
| Male | 72 | 84 | 156 |
The record gives a start of Jun 2010, a primary completion of Jul 2012 and a completion of Jul 2012. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2014, 2 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Silodosin